论文部分内容阅读
利用ＰｋＨ－２６体外标记全异基因脾细胞技术研究门脉或尾静脉注射后其在受体鼠内的早期存活动力学，并研究了枯否氏细胞与供体细胞早期存活动力学及门脉诱导免疫耐受的关系。结果表明，尾静脉注射３天内，供体细胞迅速被受体鼠排斥，而门脉注射后，供体细胞首先滞留在受体鼠肝脏内，然后逐渐向体循环转移，且滞留在肝脏内的供体细胞主要是Ｔｈｙ１．２￣＋细胞。在门脉注射后第５天，在受体鼠内仍可以测到ＰＫＨ－２６￣＋细胞。如果门脉注射前首先静脉注射枯否氏细胞阻断剂氯化铣，则不但可以阻断肝脏对门脉注射异基因供体细胞的捕获，且可阻断门脉耐受的产生。这些结果表明，受体鼠肝脏内枯否氏细胞对门脉注射异基因供体脾细胞的选择性捕获是门脉耐受诱导和维持的关键。
PkH-26 in vitro labeling of allogeneic splenocytes was used to study the early survival kinetics in portal vein or tail vein after injection into the recipient mice. The early survival kinetics and portal vein motility of Kupffer cells and donor cells Induction of immune tolerance in the relationship. The results showed that the donor cells were rapidly rejected by the recipient mice within 3 days after tail vein injection. After portal vein injection, the donor cells first remained in the liver of recipient mice and then gradually transferred to the systemic circulation, and the donor cells remained in the liver for donor Somatic cells are mainly Thy1.2 ~ + cells. On the fifth day after portal vein injection, PKH-26 ~ + cells could still be detected in recipient mice. If the first intravenous injection of Kupffer cell blocker chloride chloride before portal injection, not only can block the liver portal vein injection of allogeneic donor cells capture, and can block the generation of portal resistance. These results indicate that selective capture of allogeneic donor spleen cells by Kupffer cells in the liver of recipient mice is the key to the induction and maintenance of portal venous tolerance.